-463 G/A myeloperoxidase promoter polymorphism in giant cell arteritis

Annals of the Rheumatic Diseases

Volumn 67, Issue 4, 2008, Pages 485-488

  Salvarani, Carlo ^a   Casali, B ^a   Farnetti, E ^a   Pipitone, N ^a   Nicoli, D ^a   Macchioni, P L ^a   Cimino, L ^a   Bajocchi, G L ^a   Catanoso, M G ^a   Pattacini, L ^a   Ghinoi, A ^a   Restuccia, G ^a   Boiardi, L ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MYELOPEROXIDASE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE LOCATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GEOGRAPHY; GIANT CELL ARTERITIS; HEART MUSCLE BIOPSY; HEART MUSCLE ISCHEMIA; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROMOTER REGION; RHEUMATIC POLYMYALGIA; VISUAL IMPAIRMENT;

EID: 41849145751     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.074666     Document Type: Article

References (31)

1. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003;349:160-9.
2. Foell D, Hernandez-Rodriguez J, Sanchez M, Vogl T, Cid MC, Roth J. Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis. J Pathol 2004;204:311-16.
3. Klebanoff SJ. Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med 1980;93:480-9.
4. Lau D, Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol Ther 2006;111:16-26.
5. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996;271:14412-20.
6. Vansant G, Reynolds WF. The consensus sequence of a major Alu subfamily contains a functional retinoic acid response element. Proc Natl Acad Sci USA 1995;92:8229-33.
7. Crawford FC, Freeman MJ, Schinka JA, Morris MD, Abdullah LI, Richards D, et al. Association between Alzheimer's disease and a functional polymorphism in the myeloperoxidase gene. Exp Neurol 2001;167:456-9.
8. Zappia M, Manna I, Serra P, Cittadella R, Andreoli V, La Russa A, et al. Increased risk for Alzheimer disease with the interaction of MPO and A2M polymorphisms. Arch Neurol 2004;61:341-4.
9. Nagra RM, Becher B, Tourtellotte WW, Antel JP, Gold D, Paladino T, et al. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol 1997;78:97-107.
10. Zakrzewska-Pniewska B, Styczynska M, Podlecka A, Samocka R, Peplonska B, et al. Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis. Mult Scler 2004;10:266-71.
11. Reynolds WF, Stegeman CA, Tervaert JW. -463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis. Clin Immunol 2002;103:154-60.
12. Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 2001;142:336-9.
13. Pecoits-Filho R, Stenvinkel P, Marchlewska A, Heimbürger O, Barany B, Hoff C. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl 2003;84:172-6.
14. Asselbergs FW, Reynolds WF, Cohen-Tervaert JW, Jessurun GA, Tio RA. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med 2004;116:429-30.
15. Gonzalez-Gay MA, Boiardi L, Garcia-Porrua C, Macchioni P, Amor-Dorado JC, Salvarani C. Geographical and genetic factors do not account for significant differences in the clinical spectrum of giant cell arteritis in southern Europe. J Rheumatol 2004;31:520-3.
16. Salvarani C, Macchioni PL, Tartoni PL, Rossi F, Baricchi R, Castri C, et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol 1987;5:205-15.
17. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 1997;57:5001-3.
18. Généreau T, Peyri N, Berard M, Chérin P, Cabane J, Lehoang P, et al. Human neutrophil elastase in temporal (giant cell) arteritis: plasma and immunohistochemical studies. J Rheumatol 1998;25:710-13.
19. Kallenberg CG, Heeringa P, Stegeman CA. Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2006;2:661-70.
20. Csernok E, Lamprecht P, Gross WL. Diagnostic significance of ANCA in vasculitis. Nat Clin Pract Rheumatol 2006;2:174-5.
21. Roth J, Vogl T, Sorg C, Sunderkotter C. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol 2003;24:155-8.
22. Esteban MJ, Font C, Hernández-Rodríguez J, Valls-Solé J, Sanmartí R, Cardellach F, et al. Small-vessel vasculitis surrounding a spared temporal artery. Clinical and pathological findings in a series of twenty-eight patients. Arthritis Rheum 2001;44:1387-95.
23. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97:889-901.
24. Rodrigues MR, Rodriguez D, Russo M, Campa A. Macrophages activation includes high intracellular myeloperoxidase activity. Biochem Biophys Res Commun 2002;292:869-73.
25. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005;25:1102-11.
26. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002;347:5-12.
27. Jaremo P, Hansson G, Nilsson O. Elevated inflammatory parameters are associated with lower platelet density in acute myocardial infarctions with ST-elevation. Thromb Res 2000;100:471-8.
28. Rodriguez-Pla A, Bosch-Gil JA, Rossello-Urgell J, Huguet-Redecilla P, Stone JH, Vilardell-Tarres M. Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling. Circulation 2005;112:264-9.
29. Gonzalez-Juanatey C, Llorca J, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Gonzalez-Gay MA. Steroid therapy improves endothelial function in patients with biopsy-proven giant cell arteritis. J Rheumatol 2006;33:74-8.
30. Amoli MM, Garcia-Porrua C, Llorca J, Ollier WE, Gonzalez-Gay MA. Endothelial nitric oxide synthase haplotype associations in biopsy-proven giant cell arteritis. J Rheumatol 2003;30:2019-22.
31. Salvarani C, Casali B, Nicoli D, Farnetti E, Macchioni P, Catanoso MG, et al. Endothelial nitric oxide synthase gene polymorphisms in giant cell arteritis. Arthritis Rheum 2003;48:3219-23.